Open an account

Senti Biosciences

SNTI · NASDAQ

$0.2277+$0.0009 (+0.40%)TodayMarket closed ·
Prev close $0.2268

About SNTI

Senti Biosciences Inc is a US-based company operating in Biotechnology industry. The company is headquartered in South San Francisco, California and currently employs 39 full-time employees. The company went IPO on 2021-05-26. Senti Biosciences, Inc. and its subsidiaries is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The firm is leveraging its synthetic biology platform to engineer gene circuits into new medicines with enhanced precision and control. These gene circuits are designed to kill cancer cells, to spare healthy cells, to increase specificity to target tissues, and/or to be controllable even after administration. Its product candidates include SENTI-202 and SENTI-301A. SENTI-202 is a potential first-in-class Logic Gated off-the-shelf chimeric antigen receptor natural killer (CAR-NK) investigational cell therapy. SENTI-301A is a multi-armed off-the-shelf healthy donor-derived chimeric antigen receptor natural killer (CAR-NK) cell therapy product candidate designed for the treatment of GPC3 positive tumors.

Employees
39
Headquarters
South San Francisco, California
Listed
May 26, 2021
Sector
Health Care
Industry
Biotechnology
Website
sentibio.com

SNTI key statistics

Market cap
7.09M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
1.94M
Volume
290.81K
Open price
$0.2136
High today
$0.23
Low today
$0.2108
52 Week high
$2.88
52 Week low
$0.2122

Senti Biosciences (SNTI) at a glance

As of Oct 20, 2026, Senti Biosciences (SNTI) shares are priced at $0.2277, giving the company a market cap of 7.09M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.2108 and $0.23. The current price is 8.0% above the day's low and 1.0% below its high.

Volume so far is 290.81K shares, below the average of 1.94M shares a day.

Over the past year Senti Biosciences has ranged from $0.2122 to $2.88, and now sits 1% of the way up that range.

Senti Biosciences met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported -$0.41 per share against an estimate of -$0.2703.

The average analyst price target is $11.22, 4827.5% above the current price, from 2 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 2 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 5 analystsAvg $11.22
Low
$6.06
Now
$0.2277
High
$15.75

SNTI earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 57.3% on average.

  1. Q2 FY23: reported -$4.20 per share against an estimate of -$4.86
  2. Q3 FY23: reported $2.40 per share against an estimate of -$4.52
  3. Q4 FY24: reported -$0.67 per share against an estimate of -$3.19
  4. Q2 FY25: reported -$0.56 per share against an estimate of -$0.918
  5. Q3 FY25: reported -$0.69 per share against an estimate of -$0.578
  6. Q4 FY25: reported -$0.53 per share against an estimate of -$0.4208
  7. Q1 FY26: reported -$0.36 per share against an estimate of -$0.3672
  8. Q2 FY26: reported -$0.41 per share against an estimate of -$0.2703

SNTI news

  • Press releaseBusiness Wire

    The Radoff-JEC Group Releases Presentation Highlighting Why Seer, Inc. Stockholders Should Vote for Boardroom Change

  • Press releaseGlobe Newswire

    Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy for SENTI-202 in Relapsed/Refractory AML, Along with Important Efficacy and Durability Updates on the SENTI-202 Clinical Program

  • Press releaseGlobe Newswire

    Senti Biosciences Participates in Virtual Investor CEO Connect Segment to Discuss the Company's Groundbreaking AML Data at the American Society of Hematology Annual Meeting and Recently Granted RMAT Designation

  • Market-Moving News for December 9th

  • Press releaseGlobe Newswire

    Senti Bio Reports Third Quarter 2025 Financial Results and Confirms Next Clinical Data Readout for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) at the American Society of Hematology Annual Meeting in December

  • 12 Health Care Stocks Moving In Tuesday's Pre-Market Session

  • Press releasePRNewswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTI

  • Press releaseGlobe Newswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTI

Similar companies

Companies in the same industry as Senti Biosciences

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.